Our top pick for
Precigen, Inc is a biotechnology business based in the US. Precigen shares (PGEN) are listed on the NASDAQ and all prices are listed in US Dollars. Precigen employs 770 staff and has a trailing 12-month revenue of around USD$100.8 million.
|Latest market close||USD$8.33|
|52-week range||USD$1.26 - USD$8.8|
|50-day moving average||USD$5.5389|
|200-day moving average||USD$4.6927|
|Wall St. target price||USD$9|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-2.086|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-01-08)||-10.43%|
|1 month (2020-12-17)||1.71%|
|3 months (2020-10-15)||66.60%|
|6 months (2020-07-15)||84.29%|
|1 year (2020-01-15)||22.50%|
|2 years (2019-01-15)||1.22%|
|3 years (2018-01-15)||N/A|
|5 years (2016-01-15)||27.11|
|Revenue TTM||USD$100.8 million|
|Gross profit TTM||USD$-72,558,000|
|Return on assets TTM||-15.11%|
|Return on equity TTM||-122.87%|
|Market capitalisation||USD$1.6 billion|
TTM: trailing 12 months
There are currently 27.1 million Precigen shares held short by investors – that's known as Precigen's "short interest". This figure is 2.6% down from 27.8 million last month.
There are a few different ways that this level of interest in shorting Precigen shares can be evaluated.
Precigen's "short interest ratio" (SIR) is the quantity of Precigen shares currently shorted divided by the average quantity of Precigen shares traded daily (recently around 856985.36585366). Precigen's SIR currently stands at 31.57. In other words for every 100,000 Precigen shares traded daily on the market, roughly 31570 shares are currently held short.
However Precigen's short interest can also be evaluated against the total number of Precigen shares, or, against the total number of tradable Precigen shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Precigen's short interest could be expressed as 0.15% of the outstanding shares (for every 100,000 Precigen shares in existence, roughly 150 shares are currently held short) or 0.3365% of the tradable shares (for every 100,000 tradable Precigen shares, roughly 337 shares are currently held short).
A SIR above 20% would generally be considered very high, pointing to a pessimistic outlook for the share price, with a discouraging number of investors currently willing to bet against Precigen.
Find out more about how you can short Precigen stock.
We're not expecting Precigen to pay a dividend over the next 12 months.
Over the last 12 months, Precigen's shares have ranged in value from as little as $1.26 up to $8.8. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Precigen's is 1.7018. This would suggest that Precigen's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Precigen, Inc. discovers and develops the next generation of gene and cellular therapies in the United States. It also provides disease-modifying therapeutics; genetically engineered swine for regenerative medicine applications; proprietary methane bioconversion platform that turns natural gas into energy and chemical products; and reproductive and embryo transfer technologies. In addition, the company offers UltraVector platform that incorporates advanced DNA construction technologies and computational models to design and assemble genetic components into complex gene expression programs; mbIL15, a gene that enhances functional characteristics of immune cells; Sleeping Beauty, a non-viral transposon/transposase system; AttSite recombinases, which breaks and rejoins DNA at specific sequences; AdenoVerse technology platform, a library of engineered adenovector serotypes; and L. lactis is a food-grade bacterium. Additionally, it provides RheoSwitch inducible gene switch that provides quantitative dose-proportionate regulation of the amount and timing of target protein expression; kill switches to selectively eliminate cell therapies in vivo; UltraCAR-T platform for the treatment of cancer; AdenoVerse Immunotherapy, a library of proprietary adenovectors for the gene delivery; and ActoBiotics platform, genetically modified bacteria that deliver proteins and peptides at mucosal sites. Precigen, Inc. has collaboration and license agreements with ZIOPHARM Oncology, Inc.; Ares Trading S.A.; Oragenics, Inc.; Intrexon T1D Partners, LLC; Intrexon Energy Partners, LLC; Intrexon Energy Partners II, LLC; Fibrocell Science, Inc.; OvaXon, LLC; S & I Ophthalmic, LLC; Harvest start-up entities; and Surterra Holdings, Inc. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in January 2020. Precigen, Inc. was founded in 1998 and is based in Germantown, Maryland.
Everything we know about the Vacasa IPO, plus information on how to buy in.
Everything we know about the William Penn Bancorp IPO, plus information on how to buy in.
Everything we know about the Landos Biopharma Inc IPO, plus information on how to buy in.
Everything we know about the First High-School Education Group Co Ltd IPO, plus information on how to buy in.
Everything we know about the Knowlton Development Corp IPO, plus information on how to buy in.
Steps to owning and managing SASR, with 24-hour and historical pricing before you buy.
Steps to owning and managing SAIL, with 24-hour and historical pricing before you buy.
Steps to owning and managing SAF, with 24-hour and historical pricing before you buy.
Steps to owning and managing RDHL, with 24-hour and historical pricing before you buy.
Steps to owning and managing SBFG, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.